Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Preps To File A Rival To Lantus, But Safety Remains In Question

This article was originally published in The Pink Sheet Daily

Executive Summary

Eli Lilly’s novel basal insulin peglispro demonstrated superiority to Sanofi’s Lantus in three Phase III trials on blood sugar control, but the insulin also increased triglycerides and liver enzymes in patients.

You may also be interested in...



FDA Heparin Immunogenicity Guidance Addresses ANDA Approvals, Brand Changes

Guidance formalizes five criteria FDA used in making a “sameness” determination for Momenta/Sandoz’s enoxaparin ANDA and lays out an approach to assessing the effect of post-approval NDA changes on a product’s immunogenicity without the need for clinical trials.

On The Wings Of Lantus: Sanofi Sees Clearer Skies Ahead In Diabetes

With the removal of a near-term competitive threat to Sanofi’s hallmark insulin franchise, 2013 is poised to be a momentum-building year for the big pharma, and more specifically, its diabetes business. The opportunity can’t come too soon, as the company launches the GLP-1 agonist Lyxumia into a crowded and fiercely competitive field.

Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec

FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077196

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel